CRSP

CRISPR Therapeutics AG

research_scan theme='biotech-genomics'; value_chain_position='pure-play'; Eight disclosed candidates across ex-vivo cell (CTX112, CTX213), in-vivo CRISPR lipid editing (CTX310, CTX320, CTX321, CTX340), SyNTase platform (CTX460/AATD) and siRNA (CTX611) — the most-modality-diversified gene-editing pure-play. Casgevy royalty stream provides partial commercial de-risking but the equity is option-value-shaped at sub-$3B cap, matching the C-02 named-equity strain pattern.